Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price plummet by 11.98% in intraday trading on Tuesday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's earnings fell short of analyst expectations, overshadowing its better-than-expected revenue performance.

Kiniksa reported earnings per share (EPS) of $0.23 for Q3 2025, missing the FactSet estimate of $0.32. This significant earnings miss appears to be the primary driver behind the stock's sharp decline. However, the company's sales performance was more positive, with reported revenue of $180.855 million surpassing the estimated $167.358 million.

Despite the market's negative reaction, Kiniksa shared some optimistic projections. The company expects its 2025 Arcalyst net product revenue to be between $670 million and $675 million. Additionally, Kiniksa anticipates remaining cash flow positive on an annual basis under its current operating plan. The firm also reported progress in its product pipeline, stating it's on track for Phase 2 data from the dose-focusing portion of the KPL-387 Phase 2/3 recurrent pericarditis trial in the second half of 2026. However, these positive aspects seem to have been overshadowed by the earnings disappointment, leading to the significant stock price drop.